When analyzing the data for the T2DM patients showing disease related complications, in these cases we found a major decrease in the GLUT1 transporter level, a decrease in the GLUT3 level (controls versus T2DM complications and successfully managed patients versus those with T2DM complications), an increase in URAT1 level and in the ABCA1 level (controls versus T2DM complications, and untreated patients versus those with T2DM complications). This evidence concerns the gene SLC2A3 and type 2 diabetes mellitus.